Deep Vein Thrombosis: Evidence-Based Triage, Pharmacotherapy, and PTS Prevention

At the conclusion of this course, participants will be able to:

1. Analyze the pathophysiological mechanisms and contemporary risk factors of deep vein thrombosis to identify high-risk patients.

2. Evaluate the diagnostic accuracy of clinical prediction rules and imaging modalities to ensure precise DVT identification.

3. Implement evidence-based pharmacological management strategies, prioritizing DOACs and safety protocols, according to current clinical guidelines.

4. Develop comprehensive management plans for advanced complications and special populations to prevent long-term sequelae like post-thrombotic syndrome.

This training equips medical professionals to provide high-precision vascular care by transitioning from a mechanical stasis model to a sophisticated immunothrombotic framework. Participants will master the role of Neutrophil Extracellular Traps (NETs) in clot formation and evaluate the efficacy of age-adjusted D-dimer thresholds and the YEARS algorithm. The curriculum covers objective diagnostic markers, such as Stemmer’s sign, and individualized DOAC strategies for special populations (obesity, oncology). Learners will also gain proficiency in mechanical thrombectomy and reversal protocols to mitigate life-threatening complications and prevent long-term sequelae like post-thrombotic syndrome (PTS).

The professional practice gap addressed by this course stems from the rapid evolution of immunothrombotic research and nuanced pharmacological protocols. While baseline identification is common, clinical decision-making regarding "digital stasis" and post-viral vascular sequelae often lags behind current evidence. This activity replaces unreliable subjective markers, such as Homan’s sign, with objective, risk-stratified algorithms and the "multiple hit" risk model. Additionally, it closes competence gaps in managing high-risk subgroups, including pregnant and oncology patients, and utilizing agent-specific reversal like andexanet alfa. This training empowers providers to adjudicate between medical and mechanical interventions for optimized survival trajectories.